Mucopolysaccharidosis type 7 (MPS VII), also known as Sly syndrome, is a rare genetic disorder characterized by a deficiency of the enzyme beta-glucuronidase, leading to accumulation of mucopolysaccharides, primarily dermatan sulfate. It is a lysosomal storage disorder and is inherited in an autosomal recessive manner. Clinically, MPS VII significantly affects multiple organ systems, including the skeletal system, cardiovascular system, liver, spleen, and central nervous system. The most common symptoms include joint dysplasia, cardiomyopathy, hepatosplenomegaly, and various motor and intellectual disabilities.
History of the disease and interesting historical facts
Sly syndrome was first described in 1973, when scientists drew attention to the specificity of the manifestations of this disease. Given the rarity of MPS VII, its classification and diagnosis went through many stages. Research in the 1980s made it possible to identify a group of patients with characteristic manifestations, which contributed to the development of laboratory diagnostic methods. Consideration of clinical manifestations in different patients made it possible to identify more than 30 different mutations in the GUSB gene, which is responsible for the synthesis of beta-glucuronidase. This discovery was an important step for further genetic research and the possibility of accurate diagnosis and treatment of this disease.
Epidemiology
Mucopolysaccharidosis VII has an unusually low incidence, making it one of the rarest types of mucopolysaccharidoses. The estimated prevalence of MPS VII ranges from 1 in 1 million births to 1 in 2 million, making it more common in certain populations such as Arabs and Jewish communities. Data collected from various institutions highlight significant geographic variations in the incidence of the disease, due to ethnic and genetic factors.
Genetic predisposition to this disease
MPS VII is caused by mutations in the GUSB gene located on chromosome 7, which codes for the enzyme beta-glucuronidase. More than 30 different mutations of this gene are known, which lead to varying degrees of enzyme deficiency and, therefore, to the severity of clinical symptoms. Since MPS VII has an autosomal recessive type of inheritance, the probability of the disease appearing in the patient's heirs is 25% at birth from both parents who are carriers of the mutant gene. Genetic counseling is recommended for families in which cases of this disease have already been recorded.
Risk factors for the development of this disease
The main risk factor for the development of MPS VII is the presence of both heterozygous mutations in the GUSB gene in the future parents. Since the disease is transmitted in an autosomal recessive manner, the influence of external factors, such as physical or chemical exposure, on its occurrence is minimal. However, there are some possible factors that can aggravate the manifestations of the disease or reduce the overall quality of life of patients, namely:
- Lack of vitamin complexes necessary to maintain general health;
- Lack of adequate physical activity, which can aggravate complications associated with joint diseases;
- Psychosocial factors such as lack of support from family and society.
Diagnosis of this disease
Diagnosis of mucopolysaccharidosis VII is based on a combination of clinical manifestations and laboratory tests. The main symptoms of the disease can appear at an early age and include:
- Joint dysplasia;
- Enlargement of the liver and spleen;
- Shortsightedness and hearing impairment;
- Developmental delay and mental retardation.
Laboratory tests include beta-glucuronidase activity in leukocytes or cell culture. A urine mucopolysaccharide accumulation test may also be performed, which is an indirect sign. Radiological examinations such as X-rays, ultrasound examination of the liver and spleen are necessary to assess the structure of internal organs and joints. An important aspect is the differential diagnosis, which includes the exclusion of other types of mucopolysaccharidoses and lysosomal storage diseases.
Treatment
Currently, treatment for mucopolysaccharidosis VII is aimed at relieving symptoms and improving the quality of life of patients, as there is no specific therapy that can completely cure the disease. General approaches to treatment include:
- Pharmacological treatment to relieve symptoms - anti-inflammatory drugs and anabolic steroids are used;
- Physiotherapy to improve joint mobility and increase physical activity;
- Surgical treatment in cases of severe joint dysplasia and other structural anomalies requiring correction.
List of medications used to treat this disease
Drugs used to treat MPS VII include:
- Ibuprofen for joint pain relief;
- Diclofenac to reduce inflammation;
- Glucocorticoids to control inflammation.
Disease monitoring
Disease monitoring includes regular medical examinations, which are necessary to assess the progression of the disease and prevent possible complications. Control stages should begin at an early age and continue throughout the patient's life. The prognosis for this disease varies depending on the severity of symptoms and diseases that arise against the background of MPS VII. Complications can include respiratory failure, heart disease, and severe musculoskeletal disorders.
Age-related features of the disease
MPS VII may present clinically from early childhood, but the severity of symptoms may vary among different age groups. Neonates and young children may have more severe symptoms, while adults may have relative preservation of motor functions. However, the level of mental development may remain low regardless of age, making attention to this aspect particularly important.
Questions and Answers
- What are the main symptoms of Sly syndrome? Major symptoms include joint dysplasia, hepatosplenomegaly, mental retardation and cardiomyopathy.
- How is MPS VII diagnosed? Diagnosis is based on clinical examination, laboratory tests for beta-glucuronidase enzyme activity, and urine tests for mucopolysaccharides.
- What is the treatment for this disease? Treatment is symptomatic and includes drug therapy, physiotherapy and, in some cases, surgery.
- What is the heredity of Sly syndrome? Sly syndrome is inherited in an autosomal recessive manner, meaning that both parents must be carriers of the GUSB gene mutation.
- What is the prognosis for patients with MPS VII? The prognosis depends on the severity of the disease and can be good with early treatment and regular monitoring.
